Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Guidelines aim to establish state-regulated veterinary blood banks
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
Subscribe To Our Newsletter & Stay Updated